Eliem Therapeutics (ELYM) Competitors $1.52 -0.07 (-4.40%) As of 02/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ELYM vs. GNFT, FULC, NLTX, CYBN, SLRN, MDWD, IVVD, PLX, HURA, and PLRXShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Genfit (GNFT), Fulcrum Therapeutics (FULC), Neoleukin Therapeutics (NLTX), Cybin (CYBN), Acelyrin (SLRN), MediWound (MDWD), Invivyd (IVVD), Protalix BioTherapeutics (PLX), TuHURA Biosciences (HURA), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Genfit Fulcrum Therapeutics Neoleukin Therapeutics Cybin Acelyrin MediWound Invivyd Protalix BioTherapeutics TuHURA Biosciences Pliant Therapeutics Eliem Therapeutics (NASDAQ:ELYM) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Does the MarketBeat Community believe in ELYM or GNFT? Genfit received 60 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 69.70% of users gave Genfit an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformEliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% GenfitOutperform Votes6969.70% Underperform Votes3030.30% Do analysts rate ELYM or GNFT? Genfit has a consensus price target of $13.00, indicating a potential upside of 241.66%. Given Genfit's stronger consensus rating and higher possible upside, analysts plainly believe Genfit is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ELYM or GNFT more profitable? Genfit's return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Genfit N/A N/A N/A Which has more volatility & risk, ELYM or GNFT? Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Does the media refer more to ELYM or GNFT? In the previous week, Genfit had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Genfit and 0 mentions for Eliem Therapeutics. Genfit's average media sentiment score of 0.22 beat Eliem Therapeutics' score of 0.00 indicating that Genfit is being referred to more favorably in the news media. Company Overall Sentiment Eliem Therapeutics Neutral Genfit Neutral Do insiders and institutionals have more ownership in ELYM or GNFT? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 4.2% of Genfit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, ELYM or GNFT? Genfit has higher revenue and earnings than Eliem Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.87Genfit$41.31M4.61-$31.27MN/AN/A SummaryGenfit beats Eliem Therapeutics on 12 of the 14 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.22M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-2.876.1326.4618.82Price / SalesN/A313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book0.396.747.634.64Net Income-$35.12M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.43%-1.91%-2.66%1 Month Performance-22.05%-1.91%-0.19%-2.15%1 Year Performance-42.21%-5.03%16.70%12.90% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.52-4.4%N/A-44.5%$45.22MN/A-2.879GNFTGenfit1.2041 of 5 stars$3.92+0.3%$13.00+231.6%+4.0%$196M$41.31M0.00120FULCFulcrum Therapeutics1.8409 of 5 stars$3.63-1.6%$9.33+157.1%-59.6%$195.80M$2.81M-11.71100Upcoming EarningsNews CoverageNLTXNeoleukin TherapeuticsN/A$20.46-12.2%N/A-41.9%$192.28MN/A-6.5890News CoverageHigh Trading VolumeCYBNCybin2.3276 of 5 stars$9.37+4.1%$138.00+1,372.8%N/A$189.75MN/A-1.4150SLRNAcelyrin2.8672 of 5 stars$1.89-7.4%$9.60+407.9%-66.0%$189.62MN/A-0.77135News CoverageGap UpHigh Trading VolumeMDWDMediWound1.1795 of 5 stars$17.54-3.3%$27.50+56.8%+33.8%$189.26M$18.69M-6.0580IVVDInvivyd3.3866 of 5 stars$1.57-23.0%$7.89+402.4%-55.6%$187.80MN/A-0.80100Gap UpPLXProtalix BioTherapeutics2.189 of 5 stars$2.55-4.1%$15.00+488.2%+68.3%$187.76M$65.49M-19.62200HURATuHURA BiosciencesN/A$4.44+4.0%$13.00+192.8%N/A$187.72MN/A0.00N/ANews CoveragePLRXPliant Therapeutics4.5748 of 5 stars$3.07-60.6%$17.75+478.2%-80.6%$186.81M$1.58M-0.9290Upcoming EarningsGap DownHigh Trading Volume Related Companies and Tools Related Companies Genfit Alternatives Fulcrum Therapeutics Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives Acelyrin Alternatives MediWound Alternatives Invivyd Alternatives Protalix BioTherapeutics Alternatives TuHURA Biosciences Alternatives Pliant Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELYM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts